A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
The user experienced worsening hair loss after switching treatments and is now using generic minoxidil and finasteride. They are considering continuing finasteride, trying dutasteride, or combining treatments like mesotherapy for better results.
A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
The user has been using 1mg finasteride and 2.5mg minoxidil for hair loss but hasn't seen much change and is considering increasing minoxidil to 5mg. They plan to consult a dermatologist for further advice.
The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.
A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.
A user is starting a finasteride and minoxidil routine for diffuse pattern hair loss and is concerned about hair dependency on minoxidil. Responses suggest that new hairs may not survive without minoxidil, but existing hairs won't fall out if minoxidil is stopped, though experiences vary.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A 21-year-old has been using 1 mg of finasteride and 1 mg of oral minoxidil for 10 months with no progress and worsening hair. They are considering switching to dutasteride and are seeking success stories and advice.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.
A user is starting a hair loss treatment with a 3-in-1 spray containing 6% minoxidil, 0.3% finasteride, and 0.025% tretinoin. Users are skeptical about its effectiveness due to advanced hair loss, but some suggest adding microneedling and using affordable generics.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.
A 23-year-old male is experiencing rapid hair thinning and receding hairline, feeling emotionally drained. He has tried GFC, PRP, ketoconazole shampoo, and supplements without improvement and is considering minoxidil, finasteride, and possibly a hair transplant.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.
AB-103, a minoxidil sulfotransferase stimulant, is discussed as a potential hair loss treatment. Users inquire about effective boosters for hair growth.
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.
A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.
A user has been using a topical hair loss treatment with finasteride, minoxidil, and tretinoin for 4 years without satisfactory results and is considering switching to a different product due to concerns about effectiveness and company reliability. They are seeking others' experiences with Strut and alternative products before making a change.
User shared a 4-month progress update on using minoxidil and 1.5 months on finasteride for hair loss. Reactions were mixed, with some expressing disbelief and others feeling inspired to start treatment.